Clinical Trial Update: A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia. [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of UNR844 in presbyopia was terminated, and results were posted on 2023-08-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• UNR844

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Presbyopia | Phase 2 | Status: TERMINATED | Results posted: 2023-08-30